« Back
Home /
Migoprotafib

Migoprotafib

Item no.	HY-144903-50mg
Manufacturer	MedChem Express
CASRN	2377352-49-1
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	98.81
Citations	[1]Alexander M, et al. Shp2 phosphatase inhibitors and methods of use thereof. Patent WO2019183367A1.\|[2]Maddalo D, et al. RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy[J]. 2024.
Smiles	N[C@H]1C2(CCN(C3=CN=C(C(N4C5=CC=CN=C5CCC4)=NN6)C6=N3)CC2)OC7=CC=CC=C71
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	GDC-1971
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	ERK; p38 MAPK; Phosphatase; SHP2
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	454.53
Product Description	Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor. Migoprotafib inhibits the MAPK/ERK signaling pathway, and exhibits antitumor activity[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	MAPK/ERK Pathway; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Clinical information	Phase 1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-144903-50mg-safety-datasheet.pdf